What are the challenges for antibiotic stewardship at the community level? An analysis of the drivers of antibiotic provision by informal healthcare providers in rural India.
Antibiotic provision
Antibiotic stewardship
Antimicrobial resistance
Community settings
Drivers
India
Informal private providers
Rural
Journal
Social science & medicine (1982)
ISSN: 1873-5347
Titre abrégé: Soc Sci Med
Pays: England
ID NLM: 8303205
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
revised:
08
02
2021
accepted:
01
03
2021
pubmed:
16
3
2021
medline:
25
5
2021
entrez:
15
3
2021
Statut:
ppublish
Résumé
In many low- and middle-income countries, providers without formal training are an important source of antibiotics, but may provide these inappropriately, contributing to the rising burden of drug resistant infections. Informal providers (IPs) who practise allopathic medicine are part of India's pluralistic health system legacy. They outnumber formal providers but operate in a policy environment of unclear legitimacy, creating unique challenges for antibiotic stewardship. Using a systems approach we analysed the multiple intrinsic (provider specific) and extrinsic (community, health and regulatory system and pharmaceutical industry) drivers of antibiotic provision by IPs in rural West Bengal, to inform the design of community stewardship interventions. We surveyed 291 IPs in randomly selected village clusters in two contrasting districts and conducted in-depth interviews with 30 IPs and 17 key informants including pharmaceutical sales representatives, managers and wholesalers/retailers; medically qualified private and public doctors and health and regulatory officials. Eight focus group discussions were conducted with community members. We found a mosaic or bricolage of informal practices conducted by IPs, qualified doctors and industry stakeholders that sustained private enterprise and supplemented the weak public health sector. IPs' intrinsic drivers included misconceptions about the therapeutic necessity of antibiotics, and direct and indirect economic benefits, though antibiotics were not the most profitable category of drug sales. Private doctors were a key source of IPs' learning, often in exchange for referrals. IPs constituted a substantial market for local and global pharmaceutical companies that adopted aggressive business strategies to exploit less-saturated rural markets. Paradoxically, the top-down nature of regulations produced a regulatory impasse wherein regulators were reluctant to enforce heavy sanctions for illegal sales, fearing an adverse impact on rural healthcare, but could not implement enabling strategies to improve antibiotic provision due to legal barriers. We discuss the implications for a multi-stakeholder antibiotic stewardship strategy in this setting.
Identifiants
pubmed: 33721743
pii: S0277-9536(21)00145-3
doi: 10.1016/j.socscimed.2021.113813
pmc: PMC8164106
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
113813Subventions
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S013598/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/P004512/1
Pays : United Kingdom
Informations de copyright
Copyright © 2021. Published by Elsevier Ltd.
Références
Science. 2016 Oct 7;354(6308):
pubmed: 27846471
Soc Sci Med. 2013 Nov;96:297-304
pubmed: 23484865
PLoS One. 2019 May 31;14(5):e0217818
pubmed: 31150515
Bull World Health Organ. 2017 May 1;95(5):343-352E
pubmed: 28479635
BMC Int Health Hum Rights. 2015 Jul 04;15:17
pubmed: 26141806
Lancet Infect Dis. 2011 Sep;11(9):692-701
pubmed: 21659004
Proc Natl Acad Sci U S A. 2018 Apr 10;115(15):E3463-E3470
pubmed: 29581252
Antibiotics (Basel). 2018 Dec 22;8(1):
pubmed: 30583566
Health Policy Plan. 2015 Feb;30(1):39-55
pubmed: 24342742
Soc Sci Med. 2018 Sep;212:9-16
pubmed: 29986284
Antibiotics (Basel). 2018 Dec 18;7(4):
pubmed: 30567308
Malar J. 2013 Feb 05;12:52
pubmed: 23383972
Lancet. 2010 Dec 18;376(9758):2086-95
pubmed: 21159375
Front Public Health. 2016 Mar 31;4:57
pubmed: 27066472
Fam Pract. 2010 Dec;27(6):684-90
pubmed: 20660529
Antibiotics (Basel). 2019 Sep 05;8(3):
pubmed: 31491900
WHO South East Asia J Public Health. 2016 Sep;5(2):133-140
pubmed: 28607241
BMC Public Health. 2016 Mar 22;16:281
pubmed: 27004824
Soc Sci Med. 2020 Jun 15;:112799
pubmed: 32553441
BMJ Glob Health. 2020 Jan 30;5(1):e001864
pubmed: 32133168
Lancet Glob Health. 2018 Feb;6(2):e152-e168
pubmed: 29248365
J Antimicrob Chemother. 2019 Jan 1;74(1):256-263
pubmed: 30285113
BMC Health Serv Res. 2011 Dec 28;11:351
pubmed: 22204447
J Glob Health. 2019 Jun;9(1):010501
pubmed: 30546870
Antimicrob Resist Infect Control. 2016 Dec 20;5:58
pubmed: 28031814
Ups J Med Sci. 2014 May;119(2):117-24
pubmed: 24673267
PLoS One. 2013;8(2):e54978
pubmed: 23405101
Soc Sci Med. 2011 Feb;72(3):327-37
pubmed: 21071126
Lancet. 2018 Nov 10;392(10159):1789-1858
pubmed: 30496104
BMJ Glob Health. 2020 Sep;5(9):
pubmed: 32938614
Sociol Health Illn. 2017 May;39(4):614-628
pubmed: 27910120
Clin Infect Dis. 2013 Jul;57(2):188-96
pubmed: 23572483
BMC Pharmacol Toxicol. 2014 Feb 20;15:6
pubmed: 24555709
Health Policy Plan. 2014 Jul;29 Suppl 1:i20-9
pubmed: 25012795
BMJ Open. 2018 May 14;8(5):e021517
pubmed: 29764887
Malar J. 2020 Jul 25;19(1):270
pubmed: 32711582
J Antimicrob Chemother. 2020 Jan 1;75(1):14-29
pubmed: 31834401
Lancet. 2016 Jan 9;387(10014):176-87
pubmed: 26603922
Int J Antimicrob Agents. 2013 Mar;41(3):203-12
pubmed: 23127482
J Pers Soc Psychol. 1999 Dec;77(6):1121-34
pubmed: 10626367
Lancet. 2016 Aug 6;388(10044):613-21
pubmed: 27358250
BMJ. 2010 May 18;340:c2096
pubmed: 20483949
BMJ Glob Health. 2019 Apr 11;4(2):e001315
pubmed: 31139449
PLoS One. 2019 Jun 27;14(6):e0219002
pubmed: 31247028
BMC Int Health Hum Rights. 2010 Jul 06;10:18
pubmed: 20602805
Soc Sci Med. 2014 Jun;110:81-8
pubmed: 24727665
BMJ Glob Health. 2019 Sep 11;4(5):e001730
pubmed: 31565417
Health Aff (Millwood). 2012 May;31(5):1075-82
pubmed: 22566449
Front Public Health. 2019 Sep 02;7:239
pubmed: 31544099